Drugmaker Agios Pharmaceuticals (AGIO) shares were spiking Wednesday after announcing plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year, which TheStreet's Adam Feuerstein notes is faster than investors expected. Celgene (CELG) owns rights to the proposed drug and will be tasked with filing the new drug application, which has been described as treating patients with relapsed or refractory acute myeloid leukemia, or AML. Agios revealed its expedited plans in a Wednesday filing to the Securities and Exchange Commission, sending shares on a more than 20 percent rally. Agios shares are still down about 31 percent on the year.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.